Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis based on 2010 ACR/EULAR criteria for at least 4 months.~* At least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline.~* Hs-CRP equal or greater than 8 mg/L.~* Must have received methotrexate for at least 12 weeks and been on a stable dose for at least 4 weeks prior to the first study dose.~Exclusion Criteria:~* Evidence of untreated or inadequately treated latent or active TB.~* Evidence of uncontrolled, clinically significant diseases, including moderate or severe heart failure (NYHA Class III/IV) or malignancy in the previous 5 years.~* History of infection requiring hospitalization or parenteral antimicrobial therapy within 6 months prior to first dose of study drug.~* May have received no more than 2 doses of one biologic therapy (other than adalimumab or lymphocyte depleting therapy).~* Any second DMARD must be washed out prior to the first study dose.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-06410293 (Type: EXPERIMENTAL): None
- Adalimumab (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).